U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07593456) titled 'NST-SPARK Open-Label Phase 1 STTR (IGNITE)' on May 05.
Brief Summary: Schizophrenia Spectrum disorders (SSD) are among the most devastating psychiatric disorders. Prominent negative symptoms such as low motivation, anhedonia, asociality, and emotional flattening are experienced by up to 60% of individuals with SSD and are often considered to be the greatest contributors to functional disability. Currently, there are no FDA-approved or cleared medications or therapeutics targeting negative symptoms of schizophrenia. In this phase I proposal, North Shore Therapeutics (NST) is collaborating with the Feinstein Institutes of Medical Resea...